Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, monlunabant
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of
1d
on MSN
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
9d
Novo Loses Second Place in Danish Revenue Rankings to DSV
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...
Copenhagen Post
2d
Novo Holdings: “The challenges we face are too large for any single institution”
Marcus Remmers, a partner of the Planetary Health Investments team of Novo Holdings, the controlling shareholder of Novo ...
The Local
3d
Denmark updates salary levels for work permits in October
Denmark is updating the wage levels used to assess work permit applications from October 1st, meaning most applicants will ...
Benzinga.com
3d
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
With roughly one third of the global branded diabetes treatment market,
Novo
Nordisk
is the leading provider of ...
2d
J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
6d
Novo Nordisk A/S - share repurchase programme
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
5d
Novo loses second place in Danish revenue rankings
COPENHAGEN: Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss ...
2d
UBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Investor's Business Daily on MSN
1d
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug
Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback